Twitter LinkedIn YouTube iTune Podcast Google Podcasts Spotify

MedX Health Corp. TSXV: MDX

InvestorIntel Features on MedX Health Corp.

Now available in Spain — MedX helps detect skin cancer early.

By far the most common form of cancer is skin cancer. An estimated 4.3 million cases of basal cell carcinoma […]

Mike Druhan on the competitive advantages of MedX’s skin cancer diagnosis technology

“We have launched a new product called DermSecureTM…We can take a picture on the top of the skin of a […]

MedX set to help the early detection of skin cancer in Brazil

Skin cancer can be defined as the abnormal growth of skin cells and is often developed on skin exposed to […]

Company Overview

TeamWebsite

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

News Releases

View All News

Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify